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Background: There is a paucity of evidence for outcome predictors in patients with major depressive
disorder (MDD) not responding to initial antidepressant therapy (ADT). This post-hoc analysis evaluated
whether MDD severity affects response to adjunctive aripiprazole.
Methods: Data from 3 randomized, double-blind, placebo-controlled trials of adjunctive aripiprazole in
adults with MDD and inadequate response to 1 to 3 ADT trials were pooled and stratiﬁed based on
Montgomery–Åsberg Depression Rating Scale (MADRS) total score (mild, r24; moderate, 25–30; severe,
Z31). Treatment differences in change in MADRS total score and rates of response (Z50% MADRS
improvement) and remission (response with MADRS total score r10) were analyzed at endpoint.
Adverse events were assessed within each subgroup.
Results: Aripiprazole produced greater improvement than placebo in the MADRS total score regardless of
MDD severity at baseline (between-treatment difference [95% CI]: mild, 2.5 [4.0 to 1.1]; moderate,
3.2 [4.9 to 1.6]; severe, 4.5 [6.8 to 2.2]). Compared with placebo, adjunctive aripiprazole
increased the likelihood of response in all subgroups (risk ratio [95% CI]: mild, 1.50 [1.15, 1.95]; moderate,
1.51 [1.09, 2.11]; severe, 1.95 [1.23, 3.10]). Common treatment-emergent adverse events included
akathisia and restlessness.
Limitations: The original studies were not designed to assess the efﬁcacy of adjunctive aripiprazole
by baseline severity, and this post-hoc analysis was not powered to evaluate differences in severity
subgroups.
Conclusions: In patients who failed to respond to initial ADT, adjunctive aripiprazole was more effective
than placebo in mild, moderate, and severe MDD strata.
Clinical trial registration: ClinicalTrial.gov: NCT00095823, NCT00105196, and NCT00095758.
& 2014 Published by Elsevier B.V.
1. Introduction
Major depressive disorder (MDD) is a common, burdensome,
and often recurrent illness affecting an estimated 340 million
people worldwide (Greden, 2001). Nonresponse to antidepressant
therapy (ADT) is a frequent occurrence in clinical practice and
a major public health challenge, with up to 60% of patients not
achieving adequate response following ADT (Fava, 2003). The 2010
American Psychiatric Association (APA) guidelines for the treat-
ment of depression recommend a change in treatment after four to
eight weeks if there is inadequate response to the initial anti-
depressant (American Psychiatric Association, 2010). The change
in treatment could include altering medication dose, switching
medications, or augmentation therapy.
Ideally, selection of the next step in treatment would be based
on predictors of outcome with various strategies. Unfortunately,
evidence for predictors of outcome is limited. The large Sequenced
Treatment Alternatives to Relieve Depression (STARnD) study
identiﬁed predictors of remission but did not address what factors
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predict differential response to individual treatments (Trivedi et
al., 2006). Some guidelines have suggested that adjunctive strate-
gies might be especially useful in partial responders (American
Psychiatric Association, 2010); however, this is based on the
practical aim of maintaining improvement rather than on evidence
of efﬁcacy. In fact, aripiprazole appears to be quite effective in
nonresponders to initial treatment (Nelson et al., 2012).
The APA guidelines describe research into predictors of beneﬁt
and adverse events (AEs) as an important area of focus, and
state that severity might be a predictor of outcome. In fact, the
American Psychiatric Association guidelines recommend that
depression severity be considered as a factor when selecting
treatment (American Psychiatric Association, 2010). However, the
guidelines are unclear about how severity might guide treatment
other than advising that somatic treatments should be considered
in severe patients (as opposed to psychotherapy alone). The lack of
guidance here is again the result of limited evidence. A few reports
suggest that antidepressants produce greater improvement in
more severely depressed patients (Fournier et al., 2010; Khan et
al., 2002; Kirsch et al., 2008); however, it is unclear whether this
applies to adjunctive interventions.
Because of the lack of evidence regarding the predictive
value of severity for next-step treatments, we undertook a post-
hoc study using pooled data from three large, similarly designed
double-blind clinical trials that demonstrated the efﬁcacy of
adjunctive aripiprazole for the treatment of MDD (Berman et al.,
2007, 2009; Marcus et al., 2008). Our objective was to evaluate
whether depression severity affects the response to adjunctive
aripiprazole. Our hypothesis was that adjunctive aripiprazole
would be more effective in severely depressed patients.
2. Methods
2.1. Study design
Data were pooled from three similarly designed studies asses-
sing the efﬁcacy and safety of aripiprazole adjunctive to ADT for
the treatment of MDD. Details of the study designs were published
previously (Berman et al., 2007, 2009; Marcus et al., 2008).
The studies comprised three phases: a screening phase (Phase A,
7–28 days) during which prohibited medications were discontin-
ued; an 8-week prospective phase (Phase B), in which patients
received a selective serotonin reuptake inhibitor (SSRI) or the
serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine
extended release (XR) along with a placebo; and a 6-week
randomized, double-blind phase (Phase C) during which patients
with inadequate response received either adjunctive aripiprazole
or placebo. The antidepressants initiated in Phase B were selected
by the investigator and included escitalopram (10 or 20 mg/day),
ﬂuoxetine (20 or 40 mg/day), paroxetine controlled-release (37.5
or 50 mg/day), sertraline (100 or 150 mg/day), and venlafaxine XR
(150 or 225 mg/day). Inadequate response was deﬁned as a o50%
reduction in the 17-item Hamilton Rating Scale for Depression
(HAM-D-17) total score from baseline to the end of Phase B, HAM-
D-17 total score Z14, and Clinical Global Impressions-
Improvement (CGI-I) score Z3 at weeks 6 and 8.
The studies were conducted in accordance with the Declaration
of Helsinki; the ethics committee at each site approved the
protocol. All participants provided written consent.
2.2. Patients
Eligible patients were aged 18 to 65 years and had an MDD
diagnosis (Diagnostic and Statistical Manual of Mental Disorders –
Fourth Edition [DSM-IV-TR] criteria lasting Z8 weeks and a
HAM-D-17 total score Z18). Patients had to report an inadequate
response to 1 to 3 adequate ADT trials of Z6-week duration at or
above the minimum dose speciﬁed in the Massachusetts General
Hospital Antidepressant Treatment Response Questionnaire.
2.3. Statistical analyses
For this post-hoc analysis, patients were stratiﬁed at the begin-
ning of Phase C into 3 groups: mild (Montgomery–Åsberg Depres-
sion Rating Scale [MADRS] total score r24), moderate (MADRS
total score 25–30), and severe (MADRS total score Z31). A MADRS
total score of Z31 was previously found to best distinguish
moderate and severe depression (Muller et al., 2003), and a cutoff
of Z30 has been used in several prior studies (Bose et al., 2012;
Kennedy et al., 2009; Papakostas et al., 2012). However, the
deﬁnition of mild versus moderate depression using the MADRS
is not well established; therefore, deﬁnitions for mild and moder-
ate depression in the current study were adapted from previous
research (Kearns et al., 1982).
Adjusted mean change from Phase C baseline in MADRS total
score, CGI-Severity (CGI-S) score, and CGI-I score for adjunctive
aripiprazole and adjunctive placebo at 6 weeks was assessed using
last observation carried forward (LOCF) and an analysis of covar-
iance (ANCOVA) model, with double-blind treatment and study as
main effects and end of Phase B assessment as the covariate for
each category of baseline MADRS total score severity; results are
reported as between-group differences with 95% CIs. Rates of
response, deﬁned as Z50% improvement from baseline to end-
point in MADRS total score, and remission, deﬁned as MADRS total
score r10 at the end of Phase C (LOCF), for adjunctive aripiprazole
versus adjunctive placebo were analyzed using a Cochran–Man-
tel–Haenszel test, controlling for study and reported with 95% CIs.
A Breslow–Day test was used to test for homogeneity of the odds
ratios. To further assess the association between baseline severity
and outcome on the MADRS, a univariate logistic regression model
was used to examine the interaction of baseline severity as a
continuous variable with the drug-placebo difference in outcome
(LOCF).
Because this subgroup analysis is limited by its exploratory
post-hoc nature, including reduced power, increased variance,
and an increased inﬂuence of chance (Sleight, 2000), 95% CIs are
presented instead of P values.
3. Results
3.1. Patients
Using the described criteria for baseline severity, 415 patients
had mild depression, 385 moderate depression, and 265 severe
depression. Patient disposition and reasons for discontinuations
are summarized in Table 1. The Phase C completion rates were
high in the mild, moderate, and severe groups (90.1%, 87.8%, and
86.0%, respectively). The most common reasons for discontinua-
tion
were withdrawal of consent and AEs. The mean daily dose of
adjunctive aripiprazole at endpoint was 10.4 mg for patients with
mild depression, 11.0 mg for those with moderate depression, and
12.1 mg for those with severe depression. Baseline demographics
and psychiatric characteristics for randomized patients with mild,
moderate, and severe depression are summarized in Table 2.
Baseline mean MADRS scores were in the ranges of 20.2–20.5
among mildly depressed patients, 27.2–27.4 among moderately
depressed patients, and 33.7–34.6 among severely depressed
patients. Baseline mean CGI-S scores were 3.8 among mildly
depressed patients, 4.1 among moderately depressed patients,
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and 4.5 among severely depressed patients. For the most part,
baseline demographic and psychiatric characteristics appeared
similar across the groups, although the severe group had a slightly
smaller proportion of patients reporting atypical features and
a slightly larger proportion of patients reporting melancholic
features.
3.2. Efﬁcacy
Mean MADRS total scores for each week of Phase C are shown
in Fig. 1 by baseline severity. The differences between aripiprazole
and placebo in change in MADRS total score at endpoint were
2.5 (95% CI, 4.0 to 1.1) in the mild group, 3.2 (95% CI, 4.9
to 1.6) in the moderate group, and 4.5 (95% CI, 6.8 to 2.2)
in the severe group. Although the differences in MADRS total
scores appeared to increase with baseline severity, ANCOVA
demonstrated no signiﬁcant interaction of treatment group with
Phase C baseline severity. To further assess if baseline severity was
associated with outcome on the MADRS, we examined the
interaction of baseline severity as a continuous variable with the
drug-placebo difference in outcome. While the relationship was
signiﬁcant (Po0.001), the actual parameter estimate for the
MADRS total score at the end of Phase B was modest (0.20).
Response and remission rates at endpoint are shown in Fig. 2.
In each baseline severity subgroup, higher response rates were
reported for patients receiving adjunctive aripiprazole compared
with adjunctive placebo (Fig. 2a). Compared with placebo, aripi-
prazole treatment resulted in an increased likelihood of response
in mildly (RR [95% CI], 1.50 [1.15, 1.95]), moderately (1.51 [1.09,
2.11]), and severely depressed patients (1.95 [1.23, 3.10]). The
Breslow–Day test for homogeneity of the RRs was not statistically
signiﬁcant (P¼0.831).
Regardless of baseline severity, remission rates were higher in
patients receiving adjunctive aripiprazole versus placebo (Fig. 2b).
In mildly depressed patients, there was a greater likelihood of
achieving remission on adjunctive aripiprazole than on placebo
(RR [95% CI], 1.66 [1.28, 2.15]). Similarly, moderately depressed
patients were more likely to remit with adjunctive aripiprazole
Table 1
Patient disposition during Phase C.
Mild Moderate Severe
n (%) Aripiprazole n¼224 Placebo n¼191 Aripiprazole n¼206 Placebo n¼179 Aripiprazole n¼110 Placebo n¼155
Randomized and completed Phase B 224 191 206 179 110 155
Discontinued 26 (11.6) 15 (7.9) 28 (13.6) 19 (10.6) 17 (15.5) 20 (12.9)
Lack of efﬁcacy 0 (0.0) 1 (0.5) 2 (1.0) 4 (2.2) 5 (4.5) 3 (1.9)
Adverse event 8 (3.6) 3 (1.6) 11 (5.3) 3 (1.7) 4 (3.6) 3 (1.9)
Patient withdrew consent 6 (2.7) 4 (2.1) 5 (2.4) 5 (2.8) 3 (2.7) 7 (4.5)
Lost to follow-up 4 (1.8) 2 (1.0) 2 (1.0) 0 (0.0) 2 (1.8) 3 (1.9)
Poor/noncompliance 2 (0.9) 2 (1.0) 4 (1.9) 4 (2.2) 1 (0.9) 1 (0.6)
No longer met study criteria 4 (1.8) 1 (0.5) 4 (1.9) 2 (1.1) 2 (1.8) 3 (1.9)
Other known cause 2 (0.9) 2 (1.0) 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0)
Completed Phase C 198 (88.4) 176 (92.1) 178 (86.4) 160 (89.4) 93 (84.5) 135 (87.1)
Table 2
Patient baseline demographics and psychiatric characteristics, randomized sample.
Mild Moderate Severe
Aripiprazole n¼224 Placebo n¼191 Aripiprazole n¼206 Placebo n¼179 Aripiprazole n¼110 Placebo n¼155
Mean (SD) age, y 45.7 (11.5) 45.4 (11.0) 44.7 (10.1) 44.7 (10.5) 46.5 (10.4) 44.6 (11.1)
Women, n (%) 147 (65.6) 123 (64.4) 151 (73.3) 122 (68.2) 72 (65.5) 107 (69.0)
Race, n (%)
Black/African American 14 (6.3) 14 (7.3) 15 (7.3) 12 (6.7) 12 (10.9) 15 (9.7)
Caucasian 201 (89.7) 171 (89.5) 182 (88.3) 160 (89.4) 93 (84.5) 139 (89.7)
Other 9 (4.0) 6 (3.1) 9 (4.4) 7 (3.9) 5 (4.5) 1 (0.6)
Mean (SD) weight, kg n¼224 n¼190 n¼206 n¼178 n¼110 n¼152
84.8 (20.9) 86.6 (21.7) 85.3 (19.6) 88.2 (20.6) 86.0 (21.5) 88.6 (24.8)
Mean (SD) duration of current episode, mo 40.8 (60.5) 34.0 (51.6) 42.6 (70.7) 49.1 (78.1) 44.5 (64.0) 42.9 (63.9)
Mean (SD) number of depressive episodes n¼222 n¼190 n¼205 n¼178 n¼107 n¼155
5.2 (7.1) 6.2 (11.6) 4.6 (6.2) 6.2 (12.7) 6.8 (14.6) 4.9 (8.1)
Frequency of major depressive episode, n (%)
Recurrent 186 (83.0) 151 (79.1) 169 (82.0) 145 (81.0) 90 (81.8) 126 (81.3)
Single 38 (17.0) 40 (20.9) 37 (18.0) 34 (19.0) 20 (18.2) 29 (18.7)
Presence of atypical features, n (%) 16 (7.1) 11 (5.8) 14 (6.8) 13 (7.3) 3 (2.7) 8 (5.2)
Presence of melancholic features, n (%) 96 (42.9) 96 (50.3) 102 (49.5) 88 (49.2) 76 (69.1) 88 (56.8)
Mean (SD) MADRS total score 20.2 (3.0) 20.5 (3.1) 27.4 (1.6) 27.2 (1.7) 34.6 (3.2) 33.7 (2.6)
Mean (SD) CGI-S score 3.8 (0.5) 3.8 (0.5) 4.1 (0.5) 4.1 (0.4) 4.5 (0.6) 4.5 (0.6)
Assigned ADT, n (%)
Escitalopram 74 (33.0) 58 (30.4) 67 (32.5) 45 (25.1) 34 (30.9) 48 (31.0)
Fluoxetine 34 (15.2) 25 (13.1) 34 (16.5) 29 (16.2) 16 (14.5) 22 (14.2)
Paroxetine CR 12 (5.4) 13 (6.8) 19 (9.2) 21 (11.7) 12 (10.9) 13 (8.4)
Sertraline 42 (18.8) 41 (21.5) 26 (12.6) 30 (16.8) 21 (19.1) 33 (21.3)
Venlafaxine XR 62 (27.7) 54 (28.3) 60 (29.1) 54 (30.2) 27 (24.5) 39 (25.2)
ADT¼antidepressant therapy; CGI-S¼Clinical Global Impressions-Severity Scale; CR¼controlled release; MADRS¼Montgomery–Åsberg Depression Rating Scale;
XR¼extended release.
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than with placebo (RR [95% CI], 1.76 [1.12, 2.75]). Severely
depressed patients appeared more likely to remit with adjunctive
aripiprazole than with placebo (RR [95% CI], 1.81 [0.92, 3.59]), but
the conﬁdence interval was wide, perhaps reﬂecting both the
lower rates of remission with aripiprazole and placebo in the
severe subgroup (14.5% and 8.4%, respectively) and the smaller
size of this subgroup. The Breslow–Day test for homogeneity of the
RRs was not statistically signiﬁcant (P¼0.915).
Mean changes from baseline in CGI-S and CGI-I scores are
shown in Table 3. Patients receiving aripiprazole showed greater
improvement on the CGI-S among mildly (treatment difference
[95% CI], 0.45 [0.64, 0.25]), moderately (0.38 [0.59,
0.18]), and severely (0.39 [0.63, 0.14]) depressed patients.
Differences between adjunctive aripiprazole and placebo in all
three severity subgroups were considered clinically meaningful.
3.3. Safety and tolerability
Treatment-emergent AEs (TEAEs) reported by Z5% of patients
and at twice the rate of placebo in any treatment group are shown
in Table 4. Of these, the most common, across all three levels of
depression severity, were akathisia and restlessness.
4. Discussion
This post-hoc analysis of adjunctive aripiprazole in patients
who failed to respond to an initial trial with an SSRI or SNRI
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Fig. 1. Mean MADRS total scoren in patients with (a) mild, (b) moderate, and
(c) severe depression at baseline receiving aripiprazole or placebo adjunctive
to ADT. ANCOVA¼analysis of covariance; ADT¼antidepressant therapy; MADRS¼
Montgomery–Åsberg Depression Rating Scale. nAdjusted mean differences (95% CI)
between aripiprazole and placebo in change in MADRS total score at endpoint:
mild, 2.5 (4.0, 1.1); moderate, 3.2 (4.9, 1.6); severe, 4.5 (6.8, 2.2)
from the ANCOVA model, with double-blind treatment and study as main effects
and end of Phase B assessment as the covariate.
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Fig. 2. (a) Response and (b) remission rates at endpoint in patients receiving
aripiprazole or placebo adjunctive to ADT. ADT¼antidepressant therapy;
MADRS¼Montgomery–Åsberg Depression Rating Scale. nResponse was deﬁned as
a Z50% reduction in MADRS total score from Phase C baseline to endpoint.
†Remission was deﬁned as a MADRS total score of r10.
Table 3
CGI-S and CGI-I ratings at endpoint by baseline severity subgroup.
Mean change from baseline in CGI-S scores by severity and
treatment group
Aripiprazole Placebo Treatment comparison
Severity n Mean SE n Mean SE Difference 95% CI
Mild 224 1.23 0.07 191 0.78 0.07 0.45 0.64, 0.25
Moderate 206 1.01 0.07 179 0.63 0.08 0.38 0.59, 0.18
Severe 110 1.03 0.10 155 0.64 0.08 0.39 0.63, 0.14
Mean CGI-I scores by severity and treatment group
Aripiprazole Placebo Treatment comparison
Severity n Mean SE n Mean SE Difference 95% CI
Mild 224 2.11 0.07 191 2.48 0.07 0.36 0.56, 0.17
Moderate 206 2.50 0.07 179 2.90 0.08 0.40 0.61, 0.19
Severe 110 2.80 0.10 155 3.16 0.08 0.35 0.61, 0.10
CGI-I¼Clinical Global Impressions-Improvement; CGI-S¼Clinical Global Impres-
sions-Severity.
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(venlafaxine XR) found that treatment with aripiprazole was more
likely to result in response than placebo irrespective of MDD
severity. Differences between aripiprazole and placebo appeared
clinically meaningful.
At the outset we acknowledge that deﬁnitions of severity based
on the MADRS total score are not well established. Montgomery
and Lecrubier (1999) reported that MADRS values of 28 or 30 have
been most frequently used to deﬁne severe depression. Müller
(2003) found that a value of 431 best differentiated severe and
moderate depression; several analyses have used a threshold of
Z30 (Bose et al., 2012; Kennedy et al., 2009; Papakostas et al.,
2012). Deﬁnitions of the boundary of mild and moderate depres-
sion, however, have been variable. Based on Kearns et al. (1982),
we selected o25 as the cut-off for mild depression. The mean (SE)
baseline CGI-S value in patients with MADRS scores of 25–30 was
4.1 (0.03) for patients randomized to aripiprazole and 4.1 (0.03) for
patients randomized to placebo, indicating that this MADRS range
is consistent with the CGI-S rating of “moderate”. The mean (SE)
CGI-S score in the low severity groups (MADRSo25) was 3.8
(0.04), suggesting that this subgroup might be considered to have
mild to moderate depression.
While response rates declined as baseline severity increased,
the advantage of adjunctive aripiprazole over placebo was main-
tained for each severity level. In the adjunctive aripiprazole group,
remission rates of 48.2%, 24.3%, and 14.5% were observed in mild,
moderate, and severely ill patients, respectively. In all groups,
patients were more likely to remit with aripiprazole than with
placebo, with the highest likelihood of remission observed in the
less severely depressed patients. In short-term trials, remission
rates, which require that an absolute threshold be reached (e.g., a
MADRS scorer10), are inversely related to severity (Nelson,
2011), which is consistent with the current ﬁndings.
Collectively, our results suggest that relative efﬁcacy of adjunc-
tive aripiprazole compared with adjunctive placebo does not
meaningfully vary based on patient's baseline severity. In contrast,
several prior authors have found that the magnitude of antide-
pressant effects is greater in more severe patients (Fournier et al.,
2010; Khan et al., 2002; Kirsch et al., 2008). Based on the
interaction of baseline severity as a continuous variable with the
drug-placebo difference in outcome, our data also show greater
absolute change in more severe patients; yet, aripiprazole had
clinically meaningful effects in each of the severity groups.
4.1. Limitations
The ﬁndings reported here should be considered in light of
potential limitations, such as the post-hoc nature of the analysis
and the lack of consensus thresholds for mild, moderate, and
severe depression. Stratiﬁcation of patients into severity categories
was retrospective (adapted from Kearns (1982)) but done to
facilitate subgroup comparisons. The study was not powered to
evaluate treatment differences in the severity subgroups. In addi-
tion, no information about patient treatment history was taken
into account during the stratiﬁcation process. Treatment in Phase
B was relatively brief (8 weeks), perhaps underestimating the full
effect of ADT during a longer trial. The original three trials used
strict inclusion and exclusion criteria, possibly limiting general-
izability and applicability to clinical practice. Although patients did
not respond to 1 to 3 historical antidepressant trials before entry
into the study, many patients in real-world settings receive more
than three trials.
Some of the observations in this analysis, particularly in the
severely depressed subgroup, may be a function of trial duration. It
is possible that longer treatment, which might afford a greater
opportunity for upward titration of aripiprazole or the antidepres-
sant, may be required for recovery, especially in more severe
patients.
4.2. Implications and conclusions
The current data suggest that adjunctive aripiprazole is effec-
tive in patients who have failed to respond to a prospective trial of
an SSRI or SNRI, regardless of depression severity. Response and
remission rates with adjunctive aripiprazole were higher in mild
to moderately depressed patients compared with severely
depressed patients. The safety and tolerability proﬁle of adjunctive
aripiprazole in the current analysis was similar for all baseline
severity categories and consistent with the previous reports of
short-term safety and tolerability of adjunctive aripiprazole for
these studies (Berman et al., 2007, 2009; Marcus et al., 2008;
Nelson et al., 2009). Clinicians will need to weigh the potential
beneﬁts against the side effects and safety issues associated with
adjunctive atypical antipsychotic treatment of depression.
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Table 4
Treatment-emergent AEs (Z5% incidence and twice the rate of placebo in any treatment group) stratiﬁed by baseline MADRS total score baseline severity.
n (%) Mild Moderate Severe
Aripiprazole n¼224 Placebo n¼191 Aripiprazole n¼206 Placebo n¼179 Aripiprazole n¼110 Placebo n¼155
Akathisia 46 (20.5) 9 (4.7) 47 (22.8) 8 (4.5) 30 (27.3) 5 (3.2)
Restlessness 27 (12.1) 4 (2.1) 22 (10.7) 6 (3.4) 17 (15.5) 3 (1.9)
Fatigue 22 (9.8) 10 (5.2) 14 (6.8) 6 (3.4) 10 (9.1) 5 (3.2)
Insomnia 17 (7.6) 2 (1.0) 17 (8.3) 6 (3.4) 9 (8.2) 8 (5.2)
Somnolence 13 (5.8) 2 (1.0) 16 (7.8) 6 (3.4) – –
Blurred vision 12 (5.4) 3 (1.6) 14 (6.8) 1 (0.6) 8 (7.3) 3 (1.9)
Constipation – – 12 (5.8) 6 (3.4) 8 (7.3) 4 (2.6)
Dry mouth 5 (2.2) 10 (5.2) – – 10 (9.1) 4 (2.6)
Dizziness – – – – 10 (9.1) 5 (3.2)
Sedation – – 12 (5.8) 1 (0.6) – –
AE¼adverse event; MADRS¼Montgomery–Åsberg Depression Rating Scale. Where no value is provided, o5% of patients in both arms of that severity subgroup reported
the AE.
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